2026 Q2 - tulosraportti
81 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 989 | ||
| 7 646 | ||
| 24 999 | ||
| 1 611 | ||
| 1 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 8.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 t sitten14 BILLION DOLLARS. FIVE ACQUISITIONS. AND CIRCIO IS RIGHT IN THE MIDDLE OF THE TECHNOLOGY RACE. 🧬♟️🍷 Take a look at what Big Pharma has actually done: 💰 Eli Lilly → Kelonia: up to $7B. 💰 Eli Lilly → Orna: up to $2.4B. 💰 AbbVie → Capstan: $2.1B. 💰 Bristol Myers Squibb → Orbital: $1.5B. 💰 AstraZeneca → EsoBiotec: up to $1B. 14 BILLION DOLLARS in announced acquisition values within in-vivo cell therapy, CAR-T, and related RNA technologies. Just these five deals from 2025–2026. And in the broader biopharma market? Around 209 billion dollars distributed across 77 announced acquisitions in 2026 according to one industry overview. This is not small change. This is a global race for next-generation medicines. SO WHERE DOES CIRCIO STAND? 🧬 820 MILLION KRONER raised in 2026. 🧬 Financing horizon to 2030. 🧬 20+ active research collaborations. 🧬 Gen 5.2: approx. 200x higher gene expression in the heart. 95% heart specificity. Preclinical. 🧬 Heart. Eye. CNS. In-vivo CAR-T. 🧬 Acuitas. Nasdaq-listed Solid Biosciences. A top 5 pharma company. And now November 27 is confirmed: new in-vivo proof-of-concept data for circVec in next-generation AAV capsids will be presented. Read this one more time. Big Pharma is spending billions on technologies within the exact same emerging therapeutic areas. Circio is building a platform that could potentially have multiple applications in precisely these markets. No, Circio is not Kelonia or Orna. And the multi-billion-dollar acquisitions are no guarantee that circVec will succeed. BUT THAT IS PRECISELY WHERE THE OPPORTUNITY LIES. If the technology is validated, the risk may fall. If the risk falls, the bargaining power may increase. And if the right deals come along, the entire valuation may have to be reassessed. It is not a single stock exchange announcement I am investing for. It is the possibility that one confirmation makes the next one even more valuable. Consolidation? Volatility? Impatience? That is part of the risk of being early. The big money does not necessarily wait for the technology to become risk-free. It tries to secure it before the competition does. And if circVec actually delivers? Then the question one day might be why we were so obsessed with the share price between the milestones. We know what we own. 🧱♟️🍷
- ·7 t sittenSitting for God knows what time checking today's development on the stock exchange - and how glad I am that this is where I am 100% invested!! Everything is sailing while I/we just sit quietly with a little bit of goosebumps and take delight in sitting with this fantastic opportunity for the big jackpot 🍀 Yes.. it involves risk, but it diminishes day by day, and on top of that, there is the package deal that people can benefit from! My 46-year-old wife is unfortunately terminally ill with pancreatic cancer, but we have invested everything in this, if nothing else to help others. It is not going to save her, but for us it makes sense! What I am probably really trying to say is that even though it is the money that makes you invest in a company, this just felt right 🤞 I have faith and hope.. good wind out there ❤️Have been through that journey myself.The wife survived,but life is not as before because of the side effects she will have for the rest of her life. We then made a decision to live in warmer climes during the time of year when it is cold. This has given a different energy and quality to everyday life when the pain does not get to dominate daily life. When the return on the stock exchange makes you wake up to the sun and can start with breakfast and the sound of waves,then you feel that life can have its bright sides. That work is being done towards solutions that can give many people a better and prolonged life is probably the most rewarding thing one can do. Have myself put a pinch into Circio and know that things take time. That it fluctuates in this stock is just a part of potentially succeeding with something big for the world
- ·7 t sittenLooking at how the world's stock exchanges are being battered, I must say that Circio is holding up exceptionally well despite sell-offs and price pressure for several weeks😊 I think further that it might seem like the 9s are starting to form a rock-solid oak floor. Will be exciting to see where this ends😅
- ·9 t sittenThe shareholders in Circio are sitting tight. Market turbulence everywhere. A great many companies are shorted on the Financial Supervisory Authority's list. Not Circio. No financial risk. Cash on hand for several years. The technology is continuously presenting even sharper results, and so is the technology of selected partners. If you feel that things are taking time, realize that this is how solid medical development works. Shortcuts are no solution. That could be a disaster. A small step for cirVec science can be a giant step for the shareholders. Even though on a daily basis it might not feel like it, Circio is steadily moving forward toward the biggest thing that may have happened in Norwegian biotech. Take care of your shares.One collaboration partner after the other either receives recognition or delivers good results on their delivery technology. Even though it is a bit annoying when the share price goes down, it is quite easy to remain calm as a shareholder in Circio.
- ·10 t sittenIt is so great to have been along since price 1.1 and not sold. With the belief that those who have bought at price 15 with the same patience are going to make money. Panic has rarely paid off. Good luck everyone 🚀🧨
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
81 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 t sitten14 BILLION DOLLARS. FIVE ACQUISITIONS. AND CIRCIO IS RIGHT IN THE MIDDLE OF THE TECHNOLOGY RACE. 🧬♟️🍷 Take a look at what Big Pharma has actually done: 💰 Eli Lilly → Kelonia: up to $7B. 💰 Eli Lilly → Orna: up to $2.4B. 💰 AbbVie → Capstan: $2.1B. 💰 Bristol Myers Squibb → Orbital: $1.5B. 💰 AstraZeneca → EsoBiotec: up to $1B. 14 BILLION DOLLARS in announced acquisition values within in-vivo cell therapy, CAR-T, and related RNA technologies. Just these five deals from 2025–2026. And in the broader biopharma market? Around 209 billion dollars distributed across 77 announced acquisitions in 2026 according to one industry overview. This is not small change. This is a global race for next-generation medicines. SO WHERE DOES CIRCIO STAND? 🧬 820 MILLION KRONER raised in 2026. 🧬 Financing horizon to 2030. 🧬 20+ active research collaborations. 🧬 Gen 5.2: approx. 200x higher gene expression in the heart. 95% heart specificity. Preclinical. 🧬 Heart. Eye. CNS. In-vivo CAR-T. 🧬 Acuitas. Nasdaq-listed Solid Biosciences. A top 5 pharma company. And now November 27 is confirmed: new in-vivo proof-of-concept data for circVec in next-generation AAV capsids will be presented. Read this one more time. Big Pharma is spending billions on technologies within the exact same emerging therapeutic areas. Circio is building a platform that could potentially have multiple applications in precisely these markets. No, Circio is not Kelonia or Orna. And the multi-billion-dollar acquisitions are no guarantee that circVec will succeed. BUT THAT IS PRECISELY WHERE THE OPPORTUNITY LIES. If the technology is validated, the risk may fall. If the risk falls, the bargaining power may increase. And if the right deals come along, the entire valuation may have to be reassessed. It is not a single stock exchange announcement I am investing for. It is the possibility that one confirmation makes the next one even more valuable. Consolidation? Volatility? Impatience? That is part of the risk of being early. The big money does not necessarily wait for the technology to become risk-free. It tries to secure it before the competition does. And if circVec actually delivers? Then the question one day might be why we were so obsessed with the share price between the milestones. We know what we own. 🧱♟️🍷
- ·7 t sittenSitting for God knows what time checking today's development on the stock exchange - and how glad I am that this is where I am 100% invested!! Everything is sailing while I/we just sit quietly with a little bit of goosebumps and take delight in sitting with this fantastic opportunity for the big jackpot 🍀 Yes.. it involves risk, but it diminishes day by day, and on top of that, there is the package deal that people can benefit from! My 46-year-old wife is unfortunately terminally ill with pancreatic cancer, but we have invested everything in this, if nothing else to help others. It is not going to save her, but for us it makes sense! What I am probably really trying to say is that even though it is the money that makes you invest in a company, this just felt right 🤞 I have faith and hope.. good wind out there ❤️Have been through that journey myself.The wife survived,but life is not as before because of the side effects she will have for the rest of her life. We then made a decision to live in warmer climes during the time of year when it is cold. This has given a different energy and quality to everyday life when the pain does not get to dominate daily life. When the return on the stock exchange makes you wake up to the sun and can start with breakfast and the sound of waves,then you feel that life can have its bright sides. That work is being done towards solutions that can give many people a better and prolonged life is probably the most rewarding thing one can do. Have myself put a pinch into Circio and know that things take time. That it fluctuates in this stock is just a part of potentially succeeding with something big for the world
- ·7 t sittenLooking at how the world's stock exchanges are being battered, I must say that Circio is holding up exceptionally well despite sell-offs and price pressure for several weeks😊 I think further that it might seem like the 9s are starting to form a rock-solid oak floor. Will be exciting to see where this ends😅
- ·9 t sittenThe shareholders in Circio are sitting tight. Market turbulence everywhere. A great many companies are shorted on the Financial Supervisory Authority's list. Not Circio. No financial risk. Cash on hand for several years. The technology is continuously presenting even sharper results, and so is the technology of selected partners. If you feel that things are taking time, realize that this is how solid medical development works. Shortcuts are no solution. That could be a disaster. A small step for cirVec science can be a giant step for the shareholders. Even though on a daily basis it might not feel like it, Circio is steadily moving forward toward the biggest thing that may have happened in Norwegian biotech. Take care of your shares.One collaboration partner after the other either receives recognition or delivers good results on their delivery technology. Even though it is a bit annoying when the share price goes down, it is quite easy to remain calm as a shareholder in Circio.
- ·10 t sittenIt is so great to have been along since price 1.1 and not sold. With the belief that those who have bought at price 15 with the same patience are going to make money. Panic has rarely paid off. Good luck everyone 🚀🧨
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 989 | ||
| 7 646 | ||
| 24 999 | ||
| 1 611 | ||
| 1 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 8.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
81 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 8.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 t sitten14 BILLION DOLLARS. FIVE ACQUISITIONS. AND CIRCIO IS RIGHT IN THE MIDDLE OF THE TECHNOLOGY RACE. 🧬♟️🍷 Take a look at what Big Pharma has actually done: 💰 Eli Lilly → Kelonia: up to $7B. 💰 Eli Lilly → Orna: up to $2.4B. 💰 AbbVie → Capstan: $2.1B. 💰 Bristol Myers Squibb → Orbital: $1.5B. 💰 AstraZeneca → EsoBiotec: up to $1B. 14 BILLION DOLLARS in announced acquisition values within in-vivo cell therapy, CAR-T, and related RNA technologies. Just these five deals from 2025–2026. And in the broader biopharma market? Around 209 billion dollars distributed across 77 announced acquisitions in 2026 according to one industry overview. This is not small change. This is a global race for next-generation medicines. SO WHERE DOES CIRCIO STAND? 🧬 820 MILLION KRONER raised in 2026. 🧬 Financing horizon to 2030. 🧬 20+ active research collaborations. 🧬 Gen 5.2: approx. 200x higher gene expression in the heart. 95% heart specificity. Preclinical. 🧬 Heart. Eye. CNS. In-vivo CAR-T. 🧬 Acuitas. Nasdaq-listed Solid Biosciences. A top 5 pharma company. And now November 27 is confirmed: new in-vivo proof-of-concept data for circVec in next-generation AAV capsids will be presented. Read this one more time. Big Pharma is spending billions on technologies within the exact same emerging therapeutic areas. Circio is building a platform that could potentially have multiple applications in precisely these markets. No, Circio is not Kelonia or Orna. And the multi-billion-dollar acquisitions are no guarantee that circVec will succeed. BUT THAT IS PRECISELY WHERE THE OPPORTUNITY LIES. If the technology is validated, the risk may fall. If the risk falls, the bargaining power may increase. And if the right deals come along, the entire valuation may have to be reassessed. It is not a single stock exchange announcement I am investing for. It is the possibility that one confirmation makes the next one even more valuable. Consolidation? Volatility? Impatience? That is part of the risk of being early. The big money does not necessarily wait for the technology to become risk-free. It tries to secure it before the competition does. And if circVec actually delivers? Then the question one day might be why we were so obsessed with the share price between the milestones. We know what we own. 🧱♟️🍷
- ·7 t sittenSitting for God knows what time checking today's development on the stock exchange - and how glad I am that this is where I am 100% invested!! Everything is sailing while I/we just sit quietly with a little bit of goosebumps and take delight in sitting with this fantastic opportunity for the big jackpot 🍀 Yes.. it involves risk, but it diminishes day by day, and on top of that, there is the package deal that people can benefit from! My 46-year-old wife is unfortunately terminally ill with pancreatic cancer, but we have invested everything in this, if nothing else to help others. It is not going to save her, but for us it makes sense! What I am probably really trying to say is that even though it is the money that makes you invest in a company, this just felt right 🤞 I have faith and hope.. good wind out there ❤️Have been through that journey myself.The wife survived,but life is not as before because of the side effects she will have for the rest of her life. We then made a decision to live in warmer climes during the time of year when it is cold. This has given a different energy and quality to everyday life when the pain does not get to dominate daily life. When the return on the stock exchange makes you wake up to the sun and can start with breakfast and the sound of waves,then you feel that life can have its bright sides. That work is being done towards solutions that can give many people a better and prolonged life is probably the most rewarding thing one can do. Have myself put a pinch into Circio and know that things take time. That it fluctuates in this stock is just a part of potentially succeeding with something big for the world
- ·7 t sittenLooking at how the world's stock exchanges are being battered, I must say that Circio is holding up exceptionally well despite sell-offs and price pressure for several weeks😊 I think further that it might seem like the 9s are starting to form a rock-solid oak floor. Will be exciting to see where this ends😅
- ·9 t sittenThe shareholders in Circio are sitting tight. Market turbulence everywhere. A great many companies are shorted on the Financial Supervisory Authority's list. Not Circio. No financial risk. Cash on hand for several years. The technology is continuously presenting even sharper results, and so is the technology of selected partners. If you feel that things are taking time, realize that this is how solid medical development works. Shortcuts are no solution. That could be a disaster. A small step for cirVec science can be a giant step for the shareholders. Even though on a daily basis it might not feel like it, Circio is steadily moving forward toward the biggest thing that may have happened in Norwegian biotech. Take care of your shares.One collaboration partner after the other either receives recognition or delivers good results on their delivery technology. Even though it is a bit annoying when the share price goes down, it is quite easy to remain calm as a shareholder in Circio.
- ·10 t sittenIt is so great to have been along since price 1.1 and not sold. With the belief that those who have bought at price 15 with the same patience are going to make money. Panic has rarely paid off. Good luck everyone 🚀🧨
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 989 | ||
| 7 646 | ||
| 24 999 | ||
| 1 611 | ||
| 1 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt






